CZR
Caesars Entertainment, Inc.
CZR lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
CZR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Under pressure |
CZR's cash flow is currently healthy, and its revenue is stable, but its profitability and balance sheet are under pressure.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CZR PE Valuation
CZR has no meaningful PE right now: it lost money over the past year.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CZR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect CZR's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CZR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.61 | -$1.45 |
| Q2 2026 | -$2.27 | -$1.34 |
| Q1 2026 | -$2.36 | -$1.26 |
| Q4 2025 | -$2.42 | -$1.13 |
| Q3 2025 | -$1.16 | +$0.50 |
| Q2 2025 | -$0.93 | +$0.35 |
| Q1 2025 | -$1.10 | -131% |
| Q4 2024 | -$1.29 | -135% |
CZR is still losing money, but far less than before: $2.61 per share over the past year, against $13.50 at its worst in late 2020.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID has the edge over CZR on earnings, with more consistent year-over-year improvement.
CZR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +2.5% |
| Q2 2026 | $3B | +3% |
| Q1 2026 | $2.9B | +2.7% |
| Q4 2025 | $2.9B | +4.2% |
| Q3 2025 | $2.9B | -0.2% |
| Q2 2025 | $2.9B | +2.7% |
| Q1 2025 | $2.8B | +1.9% |
| Q4 2024 | $2.8B | -0.9% |
CZR's revenue grew through 2022 and has held roughly level since: $2.9B last quarter, up 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -2.3 points |
| Q2 2026 | 17% | -0.9 points |
| Q1 2026 | 17% | 0 points |
| Q4 2025 | 11% | -13 points |
| Q3 2025 | 18% | -4.5 points |
| Q2 2025 | 18% | +0.2 points |
| Q1 2025 | 17% | -0.2 points |
| Q4 2024 | 24% | +4.9 points |
CZR has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over CZR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CZR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $95M | -23% |
| Q2 2026 | $304M | +31% |
| Q1 2026 | $36M | +$41M |
| Q4 2025 | $147M | +390% |
| Q3 2025 | $123M | +$315M |
| Q2 2025 | $232M | +86% |
| Q1 2025 | -$5M | +$179M |
| Q4 2024 | $30M | -78% |
CZR has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CZR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.4% | -3M shares |
| 3 years | -5.6% | -12M shares |
| 5 years | -4.7% | -10M shares |
| Available history | +162% | +126M shares |
CZR has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $50M |
| Q3 2025 | $79M |
| Q4 2024 | $50M |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CZR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.3x | Elevated |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.3x | Elevated |
| Q4 2025 | 3.3x | Elevated |
| Q3 2025 | 3.0x | Elevated |
| Q2 2025 | 3.0x | Elevated |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.1x | Elevated |
CZR's net debt is about 3.3 years of its operating earnings (EBITDA), up from 3.0 years a year ago.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CZR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.5 | Neutral |
| Stochastic | 38.6 | Neutral |
CZR's weekly RSI is 55 (neutral) and its Stochastic is 39 (neutral).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CZR PE vs Consumer Cyclical Sector
| Metric | CZR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CZR has no meaningful PE right now: it lost money over the past year.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CZR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.2 | 0.1% above |
| 20 week MA | $29.6 | 1.1% below |
| 50 week MA | $27.3 | 7.2% above |
| 100 week MA | $27.6 | 6.3% above |
| 200 week MA | $35.7 | 18% below |
CZR has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CZR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $59.2 | $75.8 | +28% |
| 2021 | $75.8 | $94.8 | +25% |
| 2022 | $94.8 | $43.1 | -55% |
| 2023 | $43.1 | $46.9 | +8.8% |
| 2024 | $46.9 | $33.1 | -29% |
| 2025 | $33.1 | $24.8 | -25% |
| 2026 YTD | $24.8 | $29.3 | +18% |
CZR has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.